The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2020

Filed:

Jan. 28, 2019
Applicant:

Gene'e Tech Co., Ltd., Taipei, TW;

Inventors:

Chung-Hao Wang, Taipei, TW;

Shu-Jyuan Yang, Taipei, TW;

Chien-Ming Lee, Taipei, TW;

Assignee:

GENE'E TECH CO., LTD., New Taipei, TW;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/36 (2006.01); A61K 47/69 (2017.01); A61P 31/04 (2006.01); A61P 1/04 (2006.01); A61K 47/34 (2017.01); A61K 31/65 (2006.01); A61K 31/727 (2006.01); A61K 31/573 (2006.01); A61K 31/43 (2006.01); A61K 31/4439 (2006.01); A61K 31/415 (2006.01); A61K 31/717 (2006.01);
U.S. Cl.
CPC ...
A61K 47/36 (2013.01); A61K 47/34 (2013.01); A61K 47/6923 (2017.08); A61P 1/04 (2018.01); A61P 31/04 (2018.01); A61K 31/415 (2013.01); A61K 31/43 (2013.01); A61K 31/4439 (2013.01); A61K 31/573 (2013.01); A61K 31/65 (2013.01); A61K 31/717 (2013.01); A61K 31/727 (2013.01);
Abstract

A drug carrier, a drug structure, a purpose of the same, a method of making the same, and a method of using the same to inhibitare revealed. The drug carrier includes a negatively charged polymer, chitosan and magnetic particles. The purpose of the drug carrier is to make a drug for inhibiting. The drug structure includes a negatively charged polymer, chitosan, magnetic particles and an active ingredient. The method of making the drug structure includes mixing the negatively charged polymer solution, the chitosan solution, the magnetic particles and the active ingredient solution to form an initial solution and allowing ingredients in the initial solution to react and thereby form drug structure particles. The method of using the drug structure to inhibitincludes administering the drug structure to ancolony. The drug carrier and drug structure demonstrate enhanced therapeutic efficacy.


Find Patent Forward Citations

Loading…